Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients

[1] Ghany MG(2018)EASL recommendations on treatment of hepatitis C 2018 J Hepatol. 69 461-511

[2] Morgan TR(2020)AASLD-IDSA hepatitis C guidance panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection Hepatology 71 686-721

[3] Ioannou GN(2018)HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma J Hepatol. 68 25-32

[4] Green PK(2019)Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy Gastroenterology 156 270-280

[5] Berry K(2020)Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis Journal of viral hepatitis 27 364-373

[6] Thabut D(2020)Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding Alimentary pharmacology & therapeutics 51 458-465

[7] Bureau C(2020)HCC surveillance after SVR in patients with F3/F4 fibrosis Journal of Hepatology 74 472-480

[8] Layese R(2020)Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals Journal of hepatology 72 1924-1934

[9] McDonald SA(2020)A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis Hepatology 72 1275-1289

[10] Pollock KG(2020)Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease Hepatology 73 64-72

[1] Ghany MG(2018)EASL recommendations on treatment of hepatitis C 2018 J Hepatol. 69 461-511

[2] Morgan TR(2020)AASLD-IDSA hepatitis C guidance panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection Hepatology 71 686-721

[3] Ioannou GN(2018)HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma J Hepatol. 68 25-32

[4] Green PK(2019)Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy Gastroenterology 156 270-280

[5] Berry K(2020)Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis Journal of viral hepatitis 27 364-373

[6] Thabut D(2020)Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding Alimentary pharmacology & therapeutics 51 458-465

[7] Bureau C(2020)HCC surveillance after SVR in patients with F3/F4 fibrosis Journal of Hepatology 74 472-480

[8] Layese R(2020)Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals Journal of hepatology 72 1924-1934

[9] McDonald SA(2020)A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis Hepatology 72 1275-1289

[10] Pollock KG(2020)Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease Hepatology 73 64-72